Clinical Trials on Cholangiocarcinoma, Perihilar

Total 747 results

RedHill Biopharma Limited

Completed

A Study of ABC294640 (Yeliva ®) Alone and in Combination With Hydroxychloroquine Sulfate in Treatment of Patients With Advanced Cholangiocarcinoma

Cholangiocarcinoma | Cholangiocarcinoma Non-resectable | Cholangiocarcinoma, Perihilar | Cholangiocarcinoma, Extrahepatic | Cholangiocarcinoma, Intrahepatic

United States
RedHill Biopharma Limited

Available

Expanded Access for the Treatment of Advanced Cholangiocarcinoma With ABC294640 (Yeliva ®)

Cholangiocarcinoma | Cholangiocarcinoma Non-resectable | Cholangiocarcinoma, Perihilar | Cholangiocarcinoma, Extrahepatic | Cholangiocarcinoma, Intrahepatic
Academisch Medisch Centrum - Universiteit van Amsterdam...

Recruiting

Endoscopic Drainage of Presumed Resectable pCCA Using an Intrahepatic Plastic Stent With Retrieval String (CHORDA-II-p)

Perihilar Cholangiocarcinoma

Netherlands
Clinical Hospital Colentina
Carol Davila University of Medicine and Pharmacy; Universitatea din Bucuresti

Active, not recruiting

Endoscopy and Radiology-guided Ablation for Inoperable Cholangiocarcinoma (COMBO-RFA)

Perihilar Cholangiocarcinoma

Romania
Erasmus Medical Center

Completed

Stereotactic Body Radiation Therapy for Unresectable Perihilar Cholangiocarcinoma (STRONG)

Klatskin Tumor

Netherlands
Azienda Sanitaria Ospedaliera
Istituto Oncologico Veneto IRCCS

Recruiting

LIver TrAnspLantation for Non-resectable Peri-HIlar cholangioCArcinoma (LITALHICA) (LITALHICA)

Perihilar Cholangiocarcinoma

Italy
Academisch Medisch Centrum - Universiteit van Amsterdam...

Recruiting

Endobiliary Radiofrequency Ablation for Malignant Biliary Obstruction Due to Perihilar Cholangiocarcinoma (RACCOON)

Perihilar Cholangiocarcinoma

Netherlands
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Recruiting

PD-1 Antibody Plus GEMOX as Postoperative Adjuvant Therapy in Perihilar Cholangiocarcinoma

Perihilar Cholangiocarcinoma

China
Peking University

Recruiting

Biliary Drainage Plus HAIC in Locally Advanced pCCA

Perihilar Cholangiocarcinoma

China
Beijing Tsinghua Chang Gung Hospital

Completed

Extent of Intrahepatic Infiltration of Perihilar Cholangiocarcinoma

Perihilar Cholangiocarcinoma

China
Renyi Qin

Completed

Minimally Invasive Versus Open Surgery for PHC

Perihilar Cholangiocarcinoma

China
Concordia Laboratories Inc.

Terminated

Efficacy and Safety Study of PDT Using Photofrin in Unresectable Advanced Perihilar Cholangiocarcinoma (OPUS)

Hilar Cholangiocarcinoma

United States, Korea, Republic of, Canada, Switzerland, Germany
Tongji Hospital

Unknown

Comparing Three Dimension Laparoscopic Versus Open Surgery for Perihiliar Cholangiocarcinoma

Surgery | Cholangiocarcinoma, Perihilar

China
University of Liverpool

Completed

Long-term Morbidity After Surgery for Perihilar Cholangiocarcinoma

Surgery--Complications | Cholangiocarcinoma
Eastern Hepatobiliary Surgery Hospital

Unknown

Portal Vein Embolization Using Coils Plus TAGM vs Multiple Coils for Patients With Perihilar Cholangiocarcinoma or Hepatocellular Carcinoma

Hepatocellular Carcinoma | Cholangiocarcinoma, Perihilar | Portal Vein Occlusion | Liver; Hypertrophy, Acute

China
Central Hospital, Nancy, France

Recruiting

Prognosis of Nutritional Status for Surgical Peri Hilar Cholangiocarcinoma

Perihilar Cholangiocarcinoma

France
Central Hospital, Nancy, France

Active, not recruiting

Endoscopic Versus Radiologic Biliary Drainage for Perihilar Malignant Obstruction

Jaundice, Obstructive | Perihilar Cholangiocarcinoma

France
University of Washington
Natera, Inc.; SEngine Precision Medicine, Inc.

Recruiting

Feasibility Study of Multi-Platform Profiling of Resected Biliary Tract Cancer

Cholangiocarcinoma | Intrahepatic Cholangiocarcinoma | Hilar Cholangiocarcinoma | Biliary Tract Cancer | Gallbladder Cancer | Extrahepatic Cholangiocarcinoma | Perihilar Cholangiocarcinoma | Distal Bile Duct Cancer

United States
Seoul National University Hospital

Completed

Effect of PVE on Surgical Outcomes and Long-term Survival in Perihilar Cholangiocarcinoma

Biliary Tract Cancer | Portal Vein Embolization

Korea, Republic of
Charite University, Berlin, Germany
German Research Center for Artificial Intelligence

Not yet recruiting

Therapeutic Assistance and Decision-making Algorithms in Hepatobiliary Tumor Boards (ADBoard)

Hepatocellular Carcinoma | Intrahepatic Cholangiocarcinoma | Gallbladder Carcinoma | Cholangiocarcinoma, Perihilar | Fibrolamellar Hepatocellular Carcinoma | Metastasis to Liver

Germany
Oslo University Hospital

Recruiting

Liver Transplantation for Non-resectable Perihilar Cholangiocarcinoma (TESLA II)

Bile Duct Cancer | Klatskin Tumor | Perihilar Cholangiocarcinoma

Norway
Hannover Medical School

Completed

PiCCA Study (Panitumumab in Combination With Cisplatin/Gemcitabine) (PiCCA)

Cholangiocarcinomas

Germany
M.D. Anderson Cancer Center

Active, not recruiting

Hypofractionated Radiation Therapy and Bintrafusp Alfa for the Treatment of Advanced Intrahepatic Cholangiocarcinoma

Stage III Intrahepatic Cholangiocarcinoma AJCC v8 | Stage IIIA Intrahepatic Cholangiocarcinoma AJCC v8 | Stage IIIB Intrahepatic Cholangiocarcinoma AJCC v8 | Stage IV Intrahepatic Cholangiocarcinoma AJCC v8 | Metastatic Intrahepatic Cholangiocarcinoma | Locally Advanced Intrahepatic Cholangiocarcinoma

United States
Mayo Clinic
National Cancer Institute (NCI)

Not yet recruiting

Radioembolization With Tremelimumab and Durvalumab for Locally Advanced Unresectable or Oligo-Metastatic Intrahepatic Cholangiocarcinoma

Stage III Intrahepatic Cholangiocarcinoma AJCC v8 | Stage IV Intrahepatic Cholangiocarcinoma AJCC v8 | Unresectable Intrahepatic Cholangiocarcinoma | Locally Advanced Intrahepatic Cholangiocarcinoma | Oligometastatic Intrahepatic Cholangiocarcinoma

United States
University of Kansas Medical Center
National Cancer Institute (NCI)

Recruiting

Sacituzumab Govitecan for the Treatment for Patients With Locally Advanced, Recurrent, or Metastatic Cholangiocarcinoma

Stage III Intrahepatic Cholangiocarcinoma AJCC v8 | Metastatic Cholangiocarcinoma | Locally Advanced Cholangiocarcinoma | Stage III Hilar Cholangiocarcinoma AJCC v8 | Stage IV Hilar Cholangiocarcinoma AJCC v8 | Stage IV Intrahepatic Cholangiocarcinoma AJCC v8 | Recurrent Cholangiocarcinoma

United States
Emory University
National Cancer Institute (NCI); National Institutes of Health (NIH); Celgene

Active, not recruiting

Gemcitabine, Cisplatin, and Nab-Paclitaxel Before Surgery in Patients With High-Risk Liver Bile Duct Cancer

Resectable Cholangiocarcinoma | Stage IB Intrahepatic Cholangiocarcinoma AJCC v8 | Stage II Intrahepatic Cholangiocarcinoma AJCC v8 | Stage III Intrahepatic Cholangiocarcinoma AJCC v8 | Stage IIIA Intrahepatic Cholangiocarcinoma AJCC v8 | Stage IIIB Intrahepatic Cholangiocarcinoma AJCC v8

United States
National Cancer Institute (NCI)

Completed

Atezolizumab With or Without Cobimetinib in Treating Patients With Metastatic Bile Duct Cancer That Cannot Be Removed by Surgery or Gallbladder Cancer

Stage III Intrahepatic Cholangiocarcinoma AJCC v8 | Gallbladder Carcinoma | Metastatic Cholangiocarcinoma | Stage IV Intrahepatic Cholangiocarcinoma AJCC v8 | Unresectable Cholangiocarcinoma

United States
Emory University
National Cancer Institute (NCI)

Withdrawn

Preoperative Nab-paclitaxel, Cisplatin, and Gemcitabine Chemotherapy With or Without Infigratinib Targeted Therapy for the Treatment of Resectable Intrahepatic Cholangiocarcinoma, The OPTIC Trial

Stage II Intrahepatic Cholangiocarcinoma AJCC v8 | Stage III Intrahepatic Cholangiocarcinoma AJCC v8 | Resectable Intrahepatic Cholangiocarcinoma | Stage 0 Intrahepatic Cholangiocarcinoma AJCC v8 | Stage I Intrahepatic Cholangiocarcinoma AJCC v8

United States
AIO-Studien-gGmbH
Servier

Completed

Nal-IRI and 5-FU Compared to 5-FU in Patients With Cholangio- and Gallbladder Carcinoma Previously Treated With Gemcitabine-based Therapies (NALIRICC)

Cholangiocarcinoma Non-resectable | Cholangiocarcinoma of the Gallbladder | Cholangiocarcinoma Metastatic | Cholangiocarcinoma Advanced

Germany
Academic and Community Cancer Research United
National Cancer Institute (NCI)

Active, not recruiting

Gemcitabine and Cisplatin With Ivosidenib or Pemigatinib for the Treatment of Unresectable or Metastatic Cholangiocarcinoma

Metastatic Cholangiocarcinoma | Unresectable Cholangiocarcinoma | Advanced Cholangiocarcinoma

United States
Massachusetts General Hospital

Terminated

A Pilot Study of Neoadjuvant Therapy With Gemcitabine and Cisplatin in Patients With Resectable or Unresectable Intrahepatic Cholangiocarcinoma

Resectable Intrahepatic Cholangiocarcinoma | Unresectable Intrahepatic Cholangiocarcinoma

United States
Halozyme Therapeutics

Terminated

Study of PEGPH20 With Cisplatin (CIS) and Gemcitabine (GEM); PEGPH20 With Atezolizumab (ATEZO), CIS, and GEM; and CIS and GEM Alone in Participants With Previously Untreated, Unresectable, Locally Advanced, or Metastatic Intrahepatic and Extrahepatic Cholangiocarcinoma and Gallbladder Adenocarcinoma

Cholangiocarcinoma Non-resectable | Cholangiocarcinoma, Extrahepatic | Cholangiocarcinoma, Intrahepatic | Gallbladder Adenocarcinoma

United States, Korea, Republic of, Thailand
NRG Oncology
National Cancer Institute (NCI)

Terminated

Radiation Therapy vs. Observation Following Gemcitabine and Cisplatin for Inoperable Localized Liver Cancer

Stage III Intrahepatic Cholangiocarcinoma | Stage IVA Intrahepatic Cholangiocarcinoma

United States, Canada
Rutgers, The State University of New Jersey

Recruiting

Liver Transplantation in Intrahepatic Cholangiocarcinoma

Intrahepatic Cholangiocarcinoma | Cholangiocarcinoma, Intrahepatic

United States
Incyte Corporation

Recruiting

A Study to Evaluate the Efficacy and Safety of Pemigatinib Versus Chemotherapy in Unresectable or Metastatic Cholangiocarcinoma (FIGHT-302)

Metastatic Cholangiocarcinoma | Unresectable Cholangiocarcinoma

United States, Canada, Belgium, France, Germany, Italy, China, Spain, Japan, United Kingdom, Netherlands, Switzerland, Austria, Denmark, Finland, Ireland, Israel, Norway, Sweden
University Health Network, Toronto

Enrolling by invitation

Liver Transplant for Stable, Advanced Intrahepatic Cholangiocarcinoma

Cholangiocarcinoma, Intrahepatic

Canada
Ze-yang Ding, MD
Geneplus-Beijing Co. Ltd.; Chinese Cooperative Group of Liver Cancer (CCGLC)

Recruiting

DEB-TACE, Lenvatinib and Anti-PD(L)1 Antibody as Conversion Therapy for Intrahepatic Cholangiocarcinoma (CCGLC-009)

Cholangiocarcinoma Non-resectable

China
Beijing InnoCare Pharma Tech Co., Ltd.

Recruiting

A Study of ICP-192 in Patients With FGFR2-Rearranged Unresectable or Metastatic Intrahepatic Cholangiocarcinoma

Intrahepatic Cholangiocarcinoma (ICC)

China
Servier

Active, not recruiting

A Phase 2 Study of Ivosidenib in Previously Treated Japanese Subjects With Nonresectable or Metastatic Cholangiocarcinoma With an IDH1 Mutation

Cholangiocarcinoma Non-resectable | Cholangiocarcinoma Metastatic

Japan
University of Louisville

Withdrawn

A Study of Cisplatin or Carboplatin With Gemcitabine Versus Gemcitabine Alone as Adjuvant Therapy in Patients With Resected or Ablation Intra-Hepatic Cholangiocarcinoma

Intrahepatic Cholangiocarcinoma

United States
Tyra Biosciences, Inc

Recruiting

Safety and Anti-Tumor Activity of TYRA-200 in Advanced Cholangiocarcinoma With Activating FGFR2 Gene Alterations (SURF201)

Solid Tumor | Intrahepatic Cholangiocarcinoma | Metastatic Cholangiocarcinoma | Locally Advanced Cholangiocarcinoma

United States
Ze-yang Ding, MD
Geneplus-Beijing Co. Ltd.; Chinese Cooperative Group of Liver Cancer (CCGLC)

Recruiting

Combined HAIC, Lenvatinib and Pucotenlimab as Conversion Therapy for Unresectable Intrahepatic Cholangiocarcinoma (CCGLC-013)

Cholangiocarcinoma Non-resectable

China
Fudan University

Recruiting

Cryoablation Combined With Sintilimab Plus Lenvatinib in 1L Treatment of Advanced ICC (CASTLE-ICC-Chemo-free)

Advanced Intrahepatic Cholangiocarcinoma

China
Hutchmed

Recruiting

Phase 2 Study of HMPL-453 Tartrate in Advanced Intrahepatic Cholangiocarcinoma

Advanced Intrahepatic Cholangiocarcinoma

China
City of Hope Medical Center
National Cancer Institute (NCI)

Withdrawn

Capecitabine and Y-90 Radioembolization in Treating Patients With Advanced Bile Duct Cancer in the Liver That Cannot Be Removed by Surgery

Bile Duct Adenocarcinoma | Stage III Intrahepatic Cholangiocarcinoma | Stage IVA Intrahepatic Cholangiocarcinoma | Stage IVB Intrahepatic Cholangiocarcinoma

United States
Institut de Recherches Internationales Servier

Completed

Study of AG-120 in Previously Treated Advanced Cholangiocarcinoma With IDH1 Mutations (ClarIDHy) (ClarIDHy)

Metastatic Cholangiocarcinoma | Advanced Cholangiocarcinoma

United States, Spain, Korea, Republic of, Italy, France, United Kingdom
Shanghai Zhongshan Hospital

Unknown

Cisplatin and Gemcitabine Chemotherapy and Lenvatinib for Patients With Unresectable Intrahepatic Cholangiocarcinoma

Cholangiocarcinoma, Intrahepatic

China
Shanghai Zhongshan Hospital

Unknown

Nab-Paclitaxel Combined With Gemcitabine Adjuvant Chemotherapy After Radical Resection of Intrahepatic Cholangiocarcinoma

Cholangiocarcinoma, Intrahepatic
OHSU Knight Cancer Institute
Oregon Health and Science University

Active, not recruiting

mFOLFIRINOX Followed by Hepatic Arterial Infusion of Floxuridine and Dexamethasone With Systemic mFOLFIRI for Unresectable Liver-dominant Intrahepatic Cholangiocarcinoma

Stage III Intrahepatic Cholangiocarcinoma AJCC v8 | Stage IIIA Intrahepatic Cholangiocarcinoma AJCC v8 | Stage IIIB Intrahepatic Cholangiocarcinoma AJCC v8 | Liver and Intrahepatic Bile Duct Carcinoma | Stage IV Intrahepatic Cholangiocarcinoma AJCC v8 | Unresectable Intrahepatic Cholangiocarcinoma

United States
Hospital Vall d'Hebron

Recruiting

Liver Transplant Combined With Neoadjuvant Chemo-radiotherapy in the Treatment of Unresectable Hilar Cholangiocarcinoma. A Prospective Multicenter Study.

Unresectable Cholangiocarcinoma

Spain

Clinical Trials on Cholangiocarcinoma, Perihilar

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Mozambique

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations